Skip to main content
2024 ISPE Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Priya Bahri, PhD

Senior Lead
European Medicines Agency (EMA)
Amsterdam, Netherlands

Priya Bahri completed studies in pharmacy (University of Heidelberg) and epidemiology (McGill University) and a PhD on healthcare quality management (Humboldt University Berlin). Her continued professional development include post-graduate certificates in strategic health communication (Johns Hopkins University) and global health diplomacy (Graduate Institute Geneva).

She had gained work experience in hospital and community pharmacies and projects for health insurance companies and for the German international development agency before joining the European Medicines Agency (EMA) in 1996. There she has had responsibilities for the co-ordination of the EU pharmacovigilance system and now is the EMA's lead for pharmacovigilance and risk management guidance and policy. This includes EU-GVP and engagement of medicine users in support of evidence-based regulatory decision-making and implementation of risk minimisation measures in healthcare, as well as related research. Her work at EMA involves collaborating closely with patient, healthcare professional, academic and industry organisations in the EU, and internationally with non-EU regulators, WHO, UMC, CIOMS and ICH.

Pro bono, she is associated researcher at the Utrecht Centre for Pharmaceutical Policy and Regulation, an active member of both the International Society of Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP), and editor of the book “Communicating about Risks and Safe Use of Medicines: Real Life and Applied Research”, published by Springer in 2020.

At ISPE, she is co-founder (2012) and member of the Special Interest Group on Benefit-Risk Assessment, Communication/risk minimisation and Evaluation (ISPE BRACE SIG), and since 2020 also member of the Public Policy Committee. For the BRACE SIG, she previously was co-chair (2020-2022) and currently is the chair (2023-2025).

At ISoP, she is co-founder (2014) and coordinator of the Special Interest Group on Medicinal Product Risk Communication (ISoP CommSIG), and since 2023 also appointed member of the Scientific Board. In 2019, she was awarded as ISoP Fellow.

Disclosure information not submitted.

Presentation(s):